BNTC logo

BNTC
Benitec Biopharma Inc

6,315
Mkt Cap
$424.96M
Volume
94,555.00
52W High
$17.15
52W Low
$9.85
PE Ratio
-13.31
BNTC Fundamentals
Price
$12.62
Prev Close
$12.37
Open
$12.24
50D MA
$11.51
Beta
0.52
Avg. Volume
211,445.79
EPS (Annual)
-$1.05
P/B
2.26
Rev/Employee
$0.00
$326.64
Loading...
Loading...
News
all
press releases
PureTech Founded Entity Seaport Therapeutics Adds Intra-Cellular Therapies Founder and CEO, Dr. Sharon Mates, to its Board of Directors
PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ('PureTech' or the 'Company'), a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into value, notes...
Business Wire·6h ago
News Placeholder
More News
News Placeholder
Benitec Biopharma Limited (NASDAQ:BNTC) Receives Consensus Recommendation of "Moderate Buy" from Analysts
Shares of Benitec Biopharma Limited (NASDAQ:BNTC - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the seven analysts that are presently covering the firm...
MarketBeat·8d ago
News Placeholder
Benitec Biopharma Limited (NASDAQ:BNTC) Receives Average Recommendation of "Moderate Buy" from Brokerages
Benitec Biopharma Limited (NASDAQ:BNTC - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the seven ratings firms that are covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold rec...
MarketBeat·1mo ago
News Placeholder
Benitec Biopharma (NASDAQ:BNTC) Stock Price Crosses Above 50 Day Moving Average - What's Next?
Benitec Biopharma (NASDAQ:BNTC) Stock Price Passes Above Fifty Day Moving Average - Time to Sell...
MarketBeat·1mo ago
News Placeholder
Benitec Biopharma Reports Promising Interim Results For BB-301 Gene Therapy In OPMD Trial
(RTTNews) - Benitec Biopharma Inc. (BNTC) on Monday, announced encouraging interim results from its Phase 1b/2a clinical study evaluating BB-301, a gene therapy for Oculopharyngeal Muscular Dystrophy...
Nasdaq News: Markets·2mo ago
News Placeholder
Benitec Biopharma's (BNTC) "Buy" Rating Reaffirmed at HC Wainwright
HC Wainwright reiterated a "buy" rating and issued a $32.00 price target on shares of Benitec Biopharma in a research report on Monday...
MarketBeat·2mo ago
News Placeholder
HC Wainwright Issues Optimistic Forecast for BNTC Earnings
Benitec Biopharma Limited (NASDAQ:BNTC - Free Report) - Equities researchers at HC Wainwright boosted their Q3 2026 earnings per share estimates for Benitec Biopharma in a research report issued on...
MarketBeat·2mo ago
News Placeholder
Analysts Issue Forecasts for BNTC Q1 Earnings
Benitec Biopharma Limited (NASDAQ:BNTC - Free Report) - Investment analysts at HC Wainwright issued their Q1 2027 earnings per share estimates for shares of Benitec Biopharma in a research report...
MarketBeat·2mo ago
News Placeholder
Benitec Biopharma Limited (NASDAQ:BNTC) Receives Consensus Rating of "Moderate Buy" from Brokerages
Benitec Biopharma Limited (NASDAQ:BNTC - Get Free Report) has been assigned an average rating of "Moderate Buy" from the seven analysts that are covering the stock, MarketBeat.com reports. One...
MarketBeat·2mo ago
News Placeholder
Benitec Biopharma (NASDAQ:BNTC) Shares Cross Below 50-Day Moving Average - Here's Why
Benitec Biopharma (NASDAQ:BNTC) Share Price Passes Below 50-Day Moving Average - Time to Sell...
MarketBeat·2mo ago
<
1
2
...
>

Latest BNTC News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.